Spectral Medical

Spectral Medical Inc. is dedicated to the development and commercialization of treatments for septic shock in North America. The company offers the Endotoxin Activity Assay (EAA), a rapid in vitro diagnostic test that detects components of gram-negative bacterial cell walls, and Toraymyxin, a therapeutic hemoperfusion device designed to remove endotoxin from the bloodstream. In addition to these primary products, Spectral Medical develops, produces, and markets recombinant proteins, antibodies, and calibrators for research and development purposes, as well as proprietary reagents for use by other diagnostic firms. The company is also engaged in the development of platforms for renal replacement therapy and continuous renal replacement therapy. Founded in 1991 and headquartered in Toronto, Canada, Spectral Medical was formerly known as Spectral Diagnostics Inc. until its name change in December 2014.